LC-MS Based Platform Simplifies Access to Metabolomics for Peroxisomal Disorders

• Main Authors: Henry Gerd Klemp, Matthias Kettwig, Frank Streit, Jutta Gärtner, Hendrik Rosewich, Ralph Krätzner
• Format: Article
• Language: English
• Published: MDPI AG 2021-05-01
• Series: Metabolites
• Subjects: peroxisome biogenesis disorder; Zellweger syndrome spectrum; metabolomics; membrane lipids; biomarker; biocrates
• Online Access: https://www.mdpi.com/2218-1989/11/6/347

Peroxisomes are central hubs for cell metabolism and their dysfunction is linked to devastating human disorders, such as peroxisomal biogenesis disorders and single peroxisomal enzyme/protein deficiencies. For decades, biochemical diagnostics have been carried out using classical markers such as very long-chain fatty acids (VLCFA), which can be inconspicuous in milder and atypical cases. Holistic metabolomics studies revealed several potentially new biomarkers for peroxisomal disorders for advanced laboratory diagnostics including atypical cases. However, establishing these new markers is a major challenge in routine diagnostic laboratories. We therefore investigated whether the commercially available AbsoluteIDQ p180 kit (Biocrates Lifesciences), which utilizes flow injection and liquid chromatography mass spectrometry, may be used to reproduce some key results from previous global metabolomics studies. We applied it to serum samples from patients with mutations in peroxisomal target genes <i>PEX1</i>, <i>ABCD1</i>, and the <i>HSD17B4</i> gene. Here we found various changes in sphingomyelins and lysophosphatidylcholines. In conclusion, this kit can be used to carry out extended diagnostics for peroxisomal disorders in routine laboratories, even without access to a metabolomics unit.